In light of recent WHO classification update for glioma, how would your treatment volumes and dose prescription change for a non-enhancing molecular glioblastoma?

With the recent WHO classification redefining IDHwt tumors as glioblastoma, more patients have imaging features that are historically consistent with low-grade glioma. Would you treat surgical cavity plus residual T2 flair signal with margin to 60Gy, similar to volumes for low grade glioma? Or would you cone down from T2 flair to treat the surgical cavity where there was a more clearly defined mass similar to RTOG/NRG guidelines for glioblastoma? Louis et al., PMID 34185076